Loading
A phase 2 trial of Cobimetinib in melanoma, run by Hanmi Pharmaceutical Company Limited, now recruiting.
Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma is a phase 2 interventional study registered as NCT07449754 by Hanmi Pharmaceutical Company Limited, with 45 participants planned, started 2026-02-12 and due to reach its primary completion in 2029-09. Interventions recorded: Belvarafenib, Cobimetinib. Conditions listed: Advanced or Metastatic Melanoma. No results are recorded here; the registry entry is the source.
Shares BRAF V600-mutant melanoma, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares BRAF V600-mutant melanoma, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares BRAF V600-mutant melanoma, Advanced melanoma (unresectable stage III and stage IV), Melanoma, Small-molecule kinase inhibitors.
Shares BRAF V600-mutant melanoma, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares BRAF V600-mutant melanoma, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares BRAF V600-mutant melanoma, Melanoma.
Shares BRAF V600-mutant melanoma, Melanoma, Small-molecule kinase inhibitors.
Shares Cobimetinib, BRAF V600-mutant melanoma, Advanced melanoma (unresectable stage III and stage IV), Melanoma.